Evidence map›Paper›PMID 38654666›Full record

ArticleHaematologica2024

Differential activation of basal and IL-7-induced PI3K/Akt/ mTOR and JAK/STAT5 signaling distinguishes pediatric from adult acute lymphoblastic leukemia.

Marta B Fernandes, A Margarida Gomes, Mariana L Oliveira, Joana Caldas, Paulo Lúcio, Rathana Kim, Aurélie Caye-Eude, Filomena Pereira, Aida B De Sousa, Alessia De Stefano and 9 more

Open access · goldAbstract readComparative StudyLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 4 countries.

Marta B FernandesInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa.
A Margarida GomesInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa.
Mariana L OliveiraInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa.
Joana CaldasHospital dos Capuchos, Lisboa.
Paulo LúcioInstituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal; Champalimaud Centre for the Unknown, Lisboa.
Rathana KimHematology Laboratory, Saint-Louis Hospital, AP-HP, Paris, France; Saint-Louis Research Institute, Université de Paris, INSERM U944/Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 7212, Paris.
Aurélie Caye-EudeDépartement de Génétique, Unité de Génétique Moléculaire, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France; INSERM UMR_S1131, Institut de Recherche Saint-Louis, Université Paris-Cité, Paris.
Filomena PereiraInstituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa.
Aida B De SousaHospital dos Capuchos, Lisboa.
Alessia De StefanoInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Portugal; University of Bologna, Department of Biomedical and Neuromotor Sciences.
Matilde Y FolloUniversity of Bologna, Department of Biomedical and Neuromotor Sciences.
Maria V SoaresInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa.
João F LacerdaInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa.
Joana DesterroInstituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa.
Hélène CavéSaint-Louis Research Institute, Université de Paris, INSERM U944/Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 7212, Paris, France; Département de Génétique, Unité de Génétique Moléculaire, Hôpital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris.
Emmanuelle ClappierChampalimaud Centre for the Unknown, Lisboa, Portugal; Hematology Laboratory, Saint-Louis Hospital, AP-HP, Paris.
Ximo DuarteInstituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa.
Patrícia RibeiroHospital dos Capuchos, Lisboa.
João T BarataInstituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa. joao_barata@medicina.ulisboa.pt.
University of Lisbon · PTHospital Santo António dos Capuchos · PTCentre National de la Recherche Scientifique · FRChampalimaud Foundation · PTInserm · FRUniversity of Bologna · IT

Funding

European Research Council 101069429European Research Council 648455European Research Council 862545
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Interleukin-7Janus KinasesPhosphatidylinositol 3-KinasesPrecursor Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene Proteins c-aktSignal TransductionSTAT5 Transcription FactorTOR Serine-Threonine KinasesAdultChildHumansInterleukin-7Janus KinasesMTOR protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSTAT5 Transcription FactorTOR Serine-Threonine Kinases

Identifiers

PMID38654666
PMCPMC11290547
OpenAlexW4395113966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.